Posts filtered by tags: Allergan[x]


 

Allergan, Saint Regis Mohawk Tribe Ask SCOTUS To Hear Restasis Patent Case

A federal court last year put the kibosh on a deal whereby Allergan transferred to the tribe the Restasis patents, which the tribe then licensed back to Allergan, asserting tribal sovereign immunity to have generic companies' challenge to the patents dismissed.
Tags: Law, Courts, Allergan, Restasis


Health Canada places restrictions on Allergan's fibroid treatment Esmya

Canada's health regulator on Friday said it was restricting the use of Allergan Plc's uterine fibroid treatment Esmya after discovering a risk of serious liver injury from the drug. Health Canada said the drug, sold under brand name Fibristal in the country, should not be used by women with liver problems, or those who have had such problems in the past. It also said that more than one treatment course of the drug should be restricted to only those of childbearing age who are unable to undergo...
Tags: Science, Canada, Allergan, Health Canada, Allergan Plc


Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More

Diabetes drugs are Eli Lilly’s bread and butter, but the pharmaceutical giant hasn’t lost its appetite for cancer drugs. It grabbed hold of a few more this week by betting $8 billion on Loxo Oncology.Loxo (NASDAQ: LOXO) has made a name for itself by becoming one of just two companies ever to earn an FDA approval for a drug that targets a tumor’s DNA fingerprint, no matter where in the body that cancer is found. The drug, larotrectinib, targets rare tumor abnormalities known as NTRK fusions. The...
Tags: Deals, Startups, Ipo, Cancer, Trends, Medicare, SEC, Fda, National, GlaxoSmithKline, Allergan, Shire, Biotech, Medical Device, Postpartum Depression, Bernie Sanders


India: A Tale Of Restasis: Misadventures Of Sovereign Immunity - Khurana and Khurana

Allergan's "Restasis®" is a branded ophthalmic cyclosporine emulsion, for the treatment of chronic dry eye, with annual sales of nearly $1.5 billion.
Tags: News, India, Allergan, Khurana


A fresh crop of promising drugs is poised to change the way depression is treated for the first time in decades. Here are the ones to watch in 2019.

Researchers are on the hunt for better drugs to treat depression, a leading cause of disability worldwide. Current treatments all work in the same way, and haven't changed significantly in 35 years. Plus, they don't help as many as 1 in 3 patients. Some new drug candidates draw inspiration from psychedelics like hallucinogenic mushrooms and ketamine. Another works on a brain network called Gaba that other medications ignore. As many as one in every three people with depression does not get re...
Tags: Trends, Nasa, Peter Thiel, Silicon Valley, Columbia University, Fda, Allergan, Mars, Imperial College London, Business Insider, Johnson Johnson, Stifel, Mike Novogratz, David Nutt, GABA, Paul Matteis


Why FedEx, Allergan, and FTS International Slumped Today

Find out which stocks fell on an important day for monetary policy.
Tags: Finance, Article, Allergan, FBN, Motley Fool, Fbn/markets, Fox-business/markets, 39b6f97c-23b1-5b88-8563-9127861a2ffe


Allergan stops sale of textured breast implants in Europe, shares sink

Allergan defended the safety of its breast implants, but its shares fell 7.4 percent to $135.94 on Wednesday as some Wall Street analysts questioned whether the company would have to face any future product liability costs. France's National Agency for the Safety of Medicines & Health Products (ANSM) said late on Tuesday that it was recalling Allergan's Microcell and Biocell textured breast implants because its safety certification had not been renewed by another agency. Textured breast implan...
Tags: Europe, Science, France, United States, Allergan, MICROCELL, Safety of Medicines Health Products ANSM


Allergan stops sales of textured breast implants in Europe

Drugmaker Allergan said on Wednesday it would take its textured breast implants off the market in Europe, a day after a French regulatory body ordered the recall of the implants, which have been linked to a rare form of cancer. France's National Agency for the Safety of Medicines & Health Products (ANSM) said late Tuesday that the decision concerned Allergan's Microcell and Biocell textured breast implants. Allergan shares fell 4.5 percent in early trading.
Tags: Europe, Science, France, Allergan, MICROCELL, Biocell, Safety of Medicines Health Products ANSM


Breast implants linked to cancer withdrawn from sale in Europe

French authorities withdrew approval for Allergan textured implants, popular in UKBreast implants that have been linked to a rare form of cancer have been pulled from the market in Europe.The recall of Allergan textured implants, one of the most popular types in the UK, came after French authorities announced they had withdrawn approval for their sale in Europe. Continue reading...
Tags: Health, Europe, UK, France, Cancer, European Union, Society, World news, Allergan


Allergan stops sales in Europe of breast implants linked to cancer

The decision concerned Allergan's Microcell and Biocell products.
Tags: Europe, Finance, Article, Allergan, Reuters, FBN, Fbn/markets, Fox-business/markets, MICROCELL, 32fe164b-14e7-5af1-b962-91a378c188c2


With $42M, Ex-Ignyta CEO Aims At Cancer Again With Startup, Erasca

A year after steering cancer drug developer Ignyta into a $1.7 billion sale to Roche, Jonathan Lim is back at it again. Ignyta’s former co-founder and head executive has co-founded another biotech in San Diego, Erasca, which also wants to make new cancer therapies.Erasca on Tuesday closed a $42 million Series A round led by Lim’s own investment firm, City Hill Ventures, and Boston-based Cormorant Asset Management. Other, unnamed institutional and individual investors also participated. The comp...
Tags: Deals, Startups, Drugs, Entrepreneurship, Boston, Cancer, Trends, Vc, Autoimmune, Stem Cells, Venture Capital, San Diego, Botox, Allergan, Biotech, Life Sciences


Allergan Halts Sales in Europe of Textured Breast Implants Linked to Rare Cancer

The company’s product, in use worldwide, has been under scrutiny since women began developing a type of lymphoma.
Tags: Europe, News, France, Cancer, Plastic Surgery, Allergan, Breasts, Medical Devices, Implants, Allergan Inc, Recalls and Bans of Products, Non-Hodgkin's Lymphoma


Studio City woman claims Pasadena plastic surgeon ‘experimented’ on her and altered medical records to hide it

If money was her only goal, Wendy Knecht could have walked away when she settled her lawsuit against a Pasadena plastic surgeon for $1 million. Instead, the Studio City woman is taking her case to the state, encouraging authorities to prosecute Dr. Max Lehfeldt’s for altering her medical records after she sued the physician for using an experimental device in her breast reconstruction. Knecht claimed in her 2016 suit that she was left disfigured and forced to undergo three additional surgeries t...
Tags: Health, News, California, Sport, Hospital, Soccer, Fda, Allergan, Pasadena, Los Angeles Times, Arcadia, American Bar Association, Morgan, U S Food and Drug Administration, Sutton, Centers for Medicare


To Cover Debts, Synergy Inks $200M Bankruptcy Sale to Bausch Health

Synergy Pharmaceuticals has spent years looking for a buyer. The developer of a struggling drug for two types of chronic constipation finally has one—now that it’s gone bankrupt.New York-based Synergy (NASDAQ SGYP) cut a deal on Wednesday to sell itself to Bausch Health, a Canadian specialty pharma company, for roughly $200 million in cash. The deal is subject to an auction that will be carried out through a Chapter 11 bankruptcy filing, which allows businesses to reorganize their finances or s...
Tags: Deals, New York, Drugs, Trends, Bankruptcy, Allergan, Biotech, Life Sciences, Chapter 11, Vanguard Group, Bausch, National blog main, New York blog main, New York top stories, Boston blog main, Boston top stories


Bio Roundup: ASH Wrap, CRISPR Baby Fallout, Moderna’s Record IPO

The biggest yearly meeting for blood disease research has come and gone, and yet the stories to come out of the American Society of Hematology’s gathering in San Diego represent just a fraction of what happened in biopharma this week.Even if ASH wasn’t on your radar, the CRISPR baby saga—the apparent birth of gene edited twin girls in China that shocked the life sciences world a few weeks ago—rolled on. One massive buyout was signed, and another even bigger one inched closer to being finalized....
Tags: Deals, Startups, China, Ipo, Trends, IPOs, People, Vc, Adhd, San Diego, Astrazeneca, Fda, National, GlaxoSmithKline, Novartis, Ash


A 'party drug' with potential to be the next blockbuster antidepressant is edging closer to the mainstream, but it could set you back $9,000

Once dismissed as a "party drug," ketamine is emerging as a potential alternative treatment for depression. A growing list of academic medical centers now offer the drug, including Columbia University, which began offering ketamine to patients with severe depression this fall. Ketamine works differently from common antidepressants like Celexa or Prozac and has been called "the most important discovery in half a century." Pharmaceutical companies, including Allergan and Johnson & Johnson, are a...
Tags: New York, California, Kaiser Permanente, US, San Francisco, Trends, Harvard University, San Diego, Kaiser, Columbia University, Fda, Allergan, Ketamine, Columbia, Business Insider, Mount Sinai


A ‘party drug’ with potential to be the next blockbuster antidepressant is edging closer to the mainstream, but it could set you back $9,000

Once dismissed as a "party drug," ketamine is emerging as a potential alternative treatment for depression. A growing list of academic medical centers now offer the drug, including Columbia University, which began offering ketamine to patients with severe depression this fall. Ketamine works differently from common antidepressants like Celexa or Prozac and has been called "the most important discovery in half a century." Pharmaceutical companies including Allergan and Johnson & Johnson are als...
Tags: New York, California, Kaiser Permanente, US, San Francisco, Trends, Harvard University, San Diego, Kaiser, Columbia University, Fda, Allergan, Ketamine, Columbia, Business Insider, Mount Sinai


Roche Gains Place in NASH Race with Purchase of Jecure Therapeutics

Roche is acquiring San Diego startup Jecure Therapeutics, with hopes of turning Jecure’s early research into a drug or drugs that treat the liver disease NASH.Through its South San Francisco, CA-based Genentech division, the Swiss pharmaceutical giant will acquire Jecure, whose work has yet to reach clinical studies, the companies announced Tuesday. No financial terms were disclosed, but a Genentech spokesman said it was an all-cash deal.Nonalcoholic steatohepatitis, or NASH, is a serious form ...
Tags: Deals, San Francisco, Trends, San Diego, Fda, Allergan, Biotech, University Of California San Diego, Life Sciences, Clinical Trials, Genentech, Roche, Gilead Sciences, Nash, South San Francisco CA, Inflammation


Mirum Pharmaceuticals Launches with $120M to Advance Liver Drugs

Serial entrepreneur Mike Grey is launching a biotech enterprise with $120 million in new funding to advance two investigational liver disease drugs—one of which he has worked to develop before.Called Mirum Pharmaceuticals, the startup is developing a compound, maralixibat, to treat Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), genetic liver disorders that affect primarily children. Mirum plans to move maralixibat, its lead drug, into a Phase 3 trial next yea...
Tags: Deals, Startups, Entrepreneurship, Trends, Vc, San Diego, Fda, Pharmaceuticals, Allergan, Shire, Biotech, Liver disease, Venture Funding, New Enterprise Associates, Life Sciences, Grey


Evidence is mounting that psychedelic drugs can help treat diseases. Here are the most promising uses

There's been a recent resurgence of interest in psychedelic drugs' potential to address conditions like anxiety and depression. That research is beginning to lead to the development of new and novel drugs. Illicit drugs like mushrooms, ecstasy (MDMA), and ketamine are inspiring a range of potential treatments for diseases that currently lack good medications. Once portrayed as illegal ways to "drop out" or "tune in," psychedelic and semi-psychedelic drugs like psilocybin and ecstasy are fina...
Tags: Stanford, Trends, Ptsd, Peter Thiel, Food And Drug Administration, Silicon Valley, Fda, DEA, Allergan, Johns Hopkins, Imperial College London, Business Insider, Mdma, Johnson Johnson, Julie Holland, Mike Novogratz


Allergan says offers undervalue business units for sale, shares fall

Allergan Plc on Tuesday expressed disappointment in early offers from potential buyers for business units it has been trying to sell, and its shares fell more than 6 percent.
Tags: Money, businessNews, Allergan, Allergan Plc


Botox sales power Allergan's profit beat, forecast raise

Allergan Plc reported a higher-than-expected quarterly profit and lifted its full-year adjusted earnings forecast on Tuesday as strong sales of wrinkle injection Botox allayed some concerns around growing competition for the popular treatment.
Tags: Money, businessNews, Allergan, Allergan Plc


Indian Tribes, States, and Sovereign Immunity before the PTAB

by Dennis Crouch Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc., App. No. 18-1638 (Fed. Cir. 2018) The Federal Circuit has denied the Mohawk Tribe’s petition for en banc rehearing on the issue of whether sovereign immunity may be asserted in inter partes review (IPR) proceedings.  Although the case focused on immunity of federally recognized Indian tribes, the Federal Circuit decision is broadly written to also include patents owned by individual states.  [Fed.Cir.St.Regis.Decision] A pa...
Tags: Minnesota, Supreme Court, Law, Allergan, Patent, Fed, FMC, Patent Office, St Regis, Federal Circuit, IPR, Dennis Crouch, Fed Cir, Mylan Pharmaceuticals Inc, Iancu, Mohawk Tribe


Crown Laboratories buys Bellus Medical

Crown Laboratories, a portfolio company of Hildred Capital Partners LLC, has acquired Bellus Medical, a provider of medical aesthetics treatments. No financial terms were disclosed. Crown Laboratories is also backed by Montreux Equity Partners. PRESS RELEASE JOHNSON CITY, Tenn. & ADDISON, Texas–(BUSINESS WIRE)–Crown Laboratories, Inc. (“Crown Laboratories”), a leading, fully integrated, specialty pharmaceutical company and Hildred Capital Partners LLC (“Hildred”) portfolio company, today announc...
Tags: Trends, MB, Healthcare, M&a, Fda, Allergan, Joe, San Francisco CA, U S Food and Drug Administration FDA, Dallas Texas, Piper Jaffray, Addison TX, Montreux, Perkins Coie, Montreux Equity Partners, David Solomon


What you need to know in advertising today

Uber is eyeing a comeback. After a string of corporate disasters  dented its brand last year , the ride-hailing company seems intent on winning back hearts as it prepares for an IPO next year. Perhaps with that in mind, it just appointed Rebecca Messina as its first-ever global chief marketing officer this week. Business Insider caught up with the incoming Uber marketing chief to talk about her vision for Uber. To read the more, click here. In other news:  Google appeared before the EU's highest...
Tags: Google, Uber, Europe, France, Trends, CMO, Nike, Eu, Bloomberg, Allergan, Gawker, Jefferies, Business Insider, Gilt Groupe, State Street, Jeff Sessions


Westlake Bio Unveils $320M Fund to Put Los Angeles on the Biotech Map

Los Angeles has long been in San Francisco’s shadow when it comes to life sciences investment. But a new venture capital firm led by industry veterans is trying to cast the City of Angels in a new light.Westlake Village BioPartners is launching today with $320 million in committed capital. The Los Angeles-based firm is led by managing directors Beth Seidenberg, a former general partner at venture capital firm Kleiner Perkins, and Sean Harper, the outgoing executive vice president of research an...
Tags: Startups, Los Angeles, San Francisco, Trends, Investing, It, Vc, Venture Capital, National, Allergan, Biotech, Harper, Kleiner Perkins, beth Seidenberg, Ucla, Life Sciences


Stanford researchers are figuring out how ketamine fights depression — and why the drug has been called 'the most important discovery in half a century'

A new study from Stanford sheds light on how ketamine works in the brain to alleviate depression. The research suggests that the drug not only impacts a network of switches called the glutamate system, but also engages the opioid system — the same one that's activated by opioid painkillers. The finding could have big implications for plans to turn ketamine into the next blockbuster antidepressant. Ketamine's unique ability to staunch the symptoms of depression has earned it a new reputation ...
Tags: Stanford, San Francisco, Trends, Nasa, Astrazeneca, National Institutes of Health, Allergan, Business Insider, Johnson Johnson, Roche, Janssen, American Journal of Psychiatry, Alan Schatzberg, Schatzberg, Shawn Singh VistaGen, Allergan Johnson Johnson


Bio Roundup: EpiPen Shortage, Bluebird’s Bet, Biotech IPOs & More

It’s back-to-school season and that means it’s time to load up on school supplies. For many students and schools, one crucial item is in high demand but hard to come by: the EpiPen.Some schools stock the epinephrine autoinjectors so they can respond quickly to a student’s allergic reaction to food. Though the autoinjectors are sold by Mylan (NASDAQ: MYL), they’re made by a Pfizer (NYSE: PFE) subsidiary whose manufacturing problems have disrupted shipments. A generic version from Teva Pharmaceut...
Tags: Deals, Startups, Trends, Investing, Merck, IPOs, Mit, Food And Drug Administration, Fda, National, Pfizer, Vaccine, Allergan, Shire, Immunotherapy, Abbvie


Corrected - Allergan sues Pfizer over costs of opioid litigation

Allergan Plc on Thursday sued Pfizer Inc to force its rival to cover any damages Allergan is forced to pay as a result of hundreds of lawsuits claiming it deceptively marketed an opioid it acquired from a company Pfizer bought.
Tags: Money, businessNews, Pfizer, Allergan, Pfizer Inc, Allergan Plc


Allergan sues Pfizer over costs of opioid litigation

Allergan Plc on Thursday sued Pfizer Inc to force its larger rival to cover any damages Allergan is forced to pay as a result of hundreds of lawsuits claiming it deceptively marketed an opioid acquired from Pfizer.
Tags: Money, businessNews, Pfizer, Allergan, Pfizer Inc, Allergan Plc